title: Preoperative latanoprost to prevent ocular hypertension after phacoemulsification and intraocular lens implantation.
abstract: OBJECTIVE
  To evaluate the efficacy of latanoprost given 2 hours preoperatively to prevent ocular hypertension in the early period after phacoemulsification and posterior chamber intraocular lens (PC IOL) implantation.
  
  
  METHODS
  Departments of Ophthalmology, United Christian Hospital and Prince of Wales Hospital, Hong Kong, China.
  
  
  METHODS
  Sixty-four eyes of 64 patients with uncomplicated cataract having phacoemulsification with PC IOL implantation were included in this prospective randomized double-masked clinical trial. The eyes were randomly assigned to 1 of 2 groups: application of latanoprost 0.005% 2 hours before surgery or no latanoprost (control). Intraocular pressure (IOP) was measured 3 and 24 hours postoperatively. The anterior chamber was examined for the level of cells and flare using a slitlamp biomicroscope. The level of significance was 5%.
  
  
  RESULTS
  The decrease in the mean IOP was not statistically significantly different between eyes receiving latanoprost 2 hours preoperatively and control eyes 3 hours (P =.843) and 24 hours (P =.721) postoperatively.
  
  
  CONCLUSIONS
  A single application of latanoprost given 2 hours before phacoemulsification and PC IOL implantation did not produce a statistically significant IOP-lowering effect when compared with a control group in the first 24 hours after surgery.
authors.affiliation: Department of Ophtahlmology, United Christian Hospital, Kowloon, Hong Kong, China. jsmlai@netvigator.com
authors.forename: J S
authors.initials: JS
authors.lastname: Lai
authors.forename: A
authors.initials: A
authors.lastname: Loo
authors.forename: C C
authors.initials: CC
authors.lastname: Tham
authors.forename: S Y
authors.initials: SY
authors.lastname: Ho
authors.forename: D S
authors.initials: DS
authors.lastname: Lam
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D019654:Lens Implantation, Intraocular / Q000009:adverse effects*; D008297:Male; D009798:Ocular Hypertension / Q000209:etiology / Q000517:prevention & control*; D018918:Phacoemulsification / Q000009:adverse effects*; D011300:Preoperative Care; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost